Millions of US adults are using GLP-1 drugs in ways their prescriptions did not specify, according to a study from the Centers for Disease Control and Prevention. The study appeared in the agency's Morbidity and Mortality Weekly Report and drew on survey responses from more than 8,000 US adults collected between July and August 2025.
The researchers estimate that 9.8 percent of US adults, or about 27 million people, used a GLP-1 medication in 2025. Among those users, 44 percent reported using the drug differently than prescribed. Changes included skipping doses, delaying refills and taking smaller doses.
More than half of those who changed their use said cost or availability was the reason. The barriers were most pronounced for younger users. Of adults aged 18 to 39 who modified their use, 58 percent cited cost, compared with 20 percent of adults 65 or older.
Compounded versions were common among people who modified their use. At least 23 percent of all GLP-1 users took a compounded version, and another 9 percent said they did not know whether their drug was compounded. Among people using compounded drugs, 62 percent were not taking them as prescribed, compared with 36 percent of people using brand-name drugs.
The article reports that compounded drugs are made by compounding pharmacies and are not reviewed by the Food and Drug Administration for safety, effectiveness or quality. The CDC researchers say compounded drugs generally have higher rates of preparation errors, contamination and other manufacturing problems.
The researchers also cite a 2025 study of websites selling compounded GLP-1 drugs. That study found that nearly 40 percent of sites stated or implied the drugs were FDA-approved, and nearly 80 percent used brand names in their advertising. The CDC authors note that using brand names violates FDA standards.
The CDC authors conclude that "understanding the safety and quality of compounded GLP-1 medications is an important public health consideration." They call for more research on common modifications, such as dose and frequency changes, saying such data "could help guide the development and implementation of clinical guidelines and support appropriate medication use."